12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Encapsulated cells: Phase II data

A Phase II trial in 27 patients with pancreatic cancer showed that Nuvilex's encapsulated cells led to no immunological or cell-related adverse events. The company also said the product produced median OS and...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >